Erasca, Inc. (ERAS)
| Market Cap | 3.20B +658.2% |
| Revenue (ttm) | n/a |
| Net Income | -277.02M |
| EPS | -0.96 |
| Shares Out | 310.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,315,998 |
| Open | 10.30 |
| Previous Close | 10.23 |
| Day's Range | 10.04 - 10.54 |
| 52-Week Range | 1.06 - 24.28 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 20.30 (+97.28%) |
| Earnings Date | May 11, 2026 |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ERAS stock is "Buy." The 12-month stock price target is $20.3, which is an increase of 97.28% from the latest price.
News
Erasca Transcript: Bank of America Global Healthcare Conference 2026
ERAS-0015 shows strong efficacy and safety in key cancers, with expansion cohorts enrolling and combination studies underway. The company is advancing both pan-RAS and pan-KRAS programs, prioritizing combinations and capital efficiency to address high unmet needs in lung, pancreatic, and colorectal cancers.
Erasca price target lowered to $26 from $28 at Mizuho
Mizuho lowered the firm’s price target on Erasca (ERAS) to $26 from $28 and keeps an Outperform rating on the shares.
Erasca reports Q1 EPS (60c), consensus (23c)
“We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “The bes...
Erasca Reports First Quarter 2026 Business Updates and Financial Results
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targ...
Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck
Erasca (ERAS) announced a clinical trial collaboration and supply agreement with Merck (MRK). This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glu...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in...
Erasca to Present at the Bank of America Securities Health Care Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...
Erasca recent share selloff overdone, says JPMorgan
JPMorgan analyst Anupam Rama believes the recent weakness in shares of Erasca (ERAS) is overdone. ERAS-0015 has potential for safety differentiation and looks efficacious in non-small cell lung cancer...
H.C. Wainwright sees pressure for Erasca shares pending safety visibility
H.C. Wainwright kept a Buy rating on Erasca (ERAS) with a $20 price target after the company reported preliminary Phase 1 data for ERAS-0015. The data show a “clear step-up…
Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.
Erasca is developing a competitor to Revolution Medicines' daraxonrasib.
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS). The investigation focuses on Erasca's execut...
Erasca falls after disclosing patient died after withdrawing from trial
In a regulatory filing, Erasca (ERAS) noted that the company announced “positive” preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tu...
Erasca price target raised to $9 from $2 at BofA
BofA raised the firm’s price target on Erasca (ERAS) to $9 from $2 and keeps an Underperform rating on the shares. Following “highly-anticipated” data for ERAS0015, the firm thinks ERAS-0015…
Erasca shares sink after patient death in early-stage cancer drug trial
Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the incident was...
Erasca Transcript: Study result
Preliminary Phase I data for ERAS-0015 show strong efficacy and safety in RAS-mutated lung and pancreatic cancers, with response rates surpassing comparators and early evidence of combinability with anti-EGFR therapy. Most patients remain on treatment, and further expansion and combo data are expected in H1 2027.
Erasca announces preliminary dose escalation data for ERAS-0015
Erasca (ERAS) announced preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The preliminary data are from Erasca’s ongoing AUROR...
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE
Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
Stifel spoke with Erasca (ERAS) management this morning after the company disclosed that it received a letter from legal counsel for Revolution Medicines (RVMD) alleging that ERAS-0015 infringes certa...
Erasca sinks after Revolution Medicines alleges patent infringement
Erasca (ERAS) announced that it received a letter from legal counsel for Revolution Medicines (RVMD). In the letter Revolution alleged that Erasca’s asset ERAS-0015 is “substantially equivalent” to ce...
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
Erasca price target raised to $30 from $20 at Stifel
Stifel raised the firm’s price target on Erasca (ERAS) to $30 from $20 and keeps a Buy rating on the shares after having hosted a “confidence-inspiring” dinner with the Erasca…
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
Jefferies calls Revolution Medicines’ (RVMD) Phase 3 results in second-line pancreatic ductal adenocarcinoma “a clear win” for daraxonrasib, but adds that results were consistent with Revolution’s Pha...